<DOC>
	<DOCNO>NCT01844765</DOCNO>
	<brief_summary>To evaluate safety , efficacy concentration nilotinib time Ph+ chronic myelogenous leukemia ( CML ) pediatric patient ( 1 &lt; 18 year ) .</brief_summary>
	<brief_title>Open Label , Phase II Study Evaluate Efficacy Safety Oral Nilotinib Philadelphia Positive ( Ph+ ) Chronic Myelogenous Leukemia ( CML ) Pediatric Patients .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Neoplastic Processes</mesh_term>
	<criteria>Newly diagnose untreated Ph+ CML CP Ph+ CML CP AP resistant intolerant either imatinib dasatinib Karnofsky Lansky ≥ 50 Adequate renal , hepatic pancreatic function Potassium , magnesium , phosphorus total calcium value ≥ LLN ( low limit normal ) Written informed consent Treatment strong CYP3A4 inhibitor inducer Use plan use medication know risk possible risk prolong QT interval Acute chronic liver , pancreatic severe renal disease History pancreatitis chronic pancreatitis . Impaired cardiac function No evidence active graft v host &lt; 3mo since Stem Cell Transplant Total body irradiation ( TBI ) craniospinal radiation therapy &lt; 6months Hypersensitivity active ingredient excipients include lactose . Other protocoldefined inclusion/exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tasigna</keyword>
	<keyword>nilotinib treatment</keyword>
	<keyword>chronic phase</keyword>
	<keyword>Ph+ CML</keyword>
	<keyword>accelerate phase</keyword>
	<keyword>newly diagnose Ph+ CML</keyword>
	<keyword>pediatric</keyword>
	<keyword>24 month treatment</keyword>
</DOC>